Table 1.

Clinical and immunological parameters in relation to mutation type.

	Group A	Group B	P-value*
Recurrent sinopulmonary infections	31/61	4/19	0·033
Ig therapy	10/61	0/19	0·107
Prophylactic antibiotics	30/61	1/19	0·001
IgG low or replaced	12/56	0/19	0·03
Low or undetectable IgA	25/46†	0/19	0·00004
Low IgG2	16/27	1/11	0·01
Low pneumococcal antibodies (23-valent)	34/43	6/17	0·002
Low total lymphocyte	24/57	0/18	0·001
Count
Low T cell count	28/56	1/18	0·001
Low CD4 count	23/55	0/18	0·001
Low CD8 count	25/55	0/18	0·0003
Low B cell count	35/55	4/18	0·003

Denominator numbers vary, as not all the patients had all the tests performed. Group A patients are those with no ataxia telangiectasia mutated (ATM) kinase activity and group B patients have mutations resulting in some residual ATM kinase activity.

^*P-values refer to differences between group A and group B.

^†Of the 25 abnormal patients 22 had undetectable levels. IgA, immunoglobulin A; IgG, immunoglobulin G.